Pa Januwale 22, 2025, "Nature Medicine" idasindikiza zotsatira za Akeso payokha idapanga PD-1/CTLA-4 bispecific antibody cadonilimab pamodzi ndi oxaliplatin ndi capecitabine kuti igwiritsidwe ntchito pochiza matenda a adenocarcinoma (G/GEJ) omwe sanachiritsidwe kapena omwe sanachiritsidwe m'dera lomwelo mu kafukufuku wa Phase III (COMPASSION-15/AK104-302).Zotsatira za kafukufuku wa COMPASSION-15 zidaperekedwa kale pakamwa pa Msonkhano Wapachaka wa 2024 wa American Association for Cancer Research (AACR).
Uwu unali kafukufuku wa gawo lachitatu wochitidwa mwachisawawa, wosawoneka bwino, woyendetsedwa ndi placebo. Odwala oyenerera anali akuluakulu omwe anali ndi adenocarcinoma ya G/GEJ yomwe sinachiritsidwe, yosachira, yopitira patsogolo kapena yofalikira. Odwalawo anapatsidwa cadonilimab (10 mg kg−1 milungu itatu iliyonse) kapena placebo kuphatikiza chemotherapy (milungu itatu iliyonse). Cholinga chachikulu chinali kupulumuka konse (OS) mwa anthu omwe akufuna kuchiritsidwa (mlingo wa significance wa mbali imodzi, P = 0.025). Zotsatira zachiwiri zinaphatikizapo OS mwa odwala omwe ali ndi PD-L1 kuphatikiza positive score ≥5, kupulumuka kopanda kupita patsogolo, kuchuluka kwa yankho, nthawi yoyankha komanso chitetezo. Pofika pa 18 Ogasiti 2023, odwala 610 ochokera m'malo 75 ophunzirira adapatsidwa cadonilimab mwachisawawa (n = 305) kapena placebo (n = 305). Ndi zotsatira zapakati pa miyezi 18.7, gulu la cadonilimab linali ndi nthawi yayitali kwambiri yapakati pa opaleshoni (miyezi 14.1 poyerekeza ndi miyezi 11.1; chiŵerengero cha zoopsa (HR) 0.66; 95% nthawi yodzidalira (CI) 0.54–0.81; P < 0.001) kuposa gulu la placebo. Mapeto oyamba adakwaniritsidwa. Kupulumuka kwapakati popanda kupita patsogolo kunali miyezi 7.0 poyerekeza ndi miyezi 5.3 (HR 0.53, 95% CI 0.44–0.65). Odwala omwe ali ndi PD-L1 adaphatikiza chigoli chabwino ≥5 anali miyezi 15.3 poyerekeza ndi miyezi 10.9 (HR 0.58, 95% CI 0.41–0.82). Chiŵerengero cha mayankho olondola chinali 65.2% poyerekeza ndi 48.9% ndi nthawi yapakati yoyankha ya miyezi 8.8 poyerekeza ndi miyezi 4.4. Zochitika zoyipa zokhudzana ndi chithandizo cha giredi ≥3 zidachitika mwa 65.9% ya gulu la cadonilimab ndi 53.6% ya gulu la placebo, ndipo zofala kwambiri zinali kuchepa kwa kuchuluka kwa ma platelet, kuchepa kwa kuchuluka kwa ma neutrophil ndi kuchepa kwa magazi m'thupi. Zochitika zambiri zoyipa zokhudzana ndi chitetezo cha mthupi zinali giredi 1 kapena 2. Palibe zizindikiro zatsopano zachitetezo zomwe zidawonedwa. Cadonilimab kuphatikiza chemotherapy zidasintha kwambiri OS ndi mbiri yabwino yotetezeka mwa odwala omwe ali ndi G/GEJ adenocarcinoma yapamwamba.
Jakisoni wa Cadonilimab ndi mankhwala atsopano, oyamba mu kalasi ya PD-1/CTLA-4 omwe adapangidwa m'nyumba. Pa June 29, 2022, Cadonilimab yavomerezedwa ndi NMPA ya ku China kuti ichite chithandizo cha odwala khansa ya pachibelekero (R/M CC) omwe adabwereranso kapena atapitirira pa chemotherapy yokhala ndi platinum. Mu Seputembala 2024, chizindikiro chatsopano cha cadonilimab chavomerezedwa kuti chigwiritsidwe ntchito pochiza odwala omwe ali ndi adenocarcinoma (G/GEJ) adenocarcinoma, yomwe singathe kuchiritsidwa kapena kufalikira, pamodzi ndi fluoropyrimidine ndi chemotherapy yokhala ndi platinum. Pakadali pano, kugwiritsa ntchito mankhwala atsopano a Cadonilimab pamodzi ndi chemotherapy yokhala ndi platinum, yokhala ndi bevacizumab kapena yopanda, pochiza khansa ya pachibelekero yomwe ikupitiliza, yobwerezabwereza, kapena yofalikira kwa khansa ya pachibelekero yavomerezedwa ndi CDE. Kuphatikiza apo, maphunziro angapo azachipatala, kuphatikizapo mayeso a gawo lachitatu a chithandizo chothandizira odwala omwe ali ndi chiopsezo chachikulu chobwereranso pambuyo pochotsa khansa ya chiwindi, akuchitidwa bwino.
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Email：myimmnet@163.com
Zolemba
https://www.nature.com/articles/s41591-024-03450-4
Nthawi yotumizira: Feb-21-2025